Boston Scientific Receives Industry’s First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients

Boston Scientific’s ION Paclitaxel-Eluting Platinum Chromium Coronary Stent system and TAXUS Liberte Paclitaxel-Eluting Coronary Stent system have received U.S. Food and Drug Administration approval for use in patients experiencing an acute myocardial infarction, or heart attack.
Bradenton Herald